Sarepta Therapeutics/SRPT

$136.14

1.13%
-
1D1W1MYTD1YMAX

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Ticker
SRPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Douglas Ingram
Employees
1,162
Headquarters
Cambridge, United States

SRPT Metrics

BasicAdvanced
$12.59B
Market cap
-
P/E ratio
-$7.83
EPS
0.94
Beta
-
Dividend rate

What the Analysts think about SRPT

Analyst Ratings

Majority rating from 24 analysts.
Buy

Price Targets

Average projection from 20 analysts.
17.34% upside
High $224.00
Low $103.00
$136.14
Current price
$159.74
Average price target

SRPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12.32% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$331.8M
27.03%
Net income
$-40.9M
71.13%
Profit margin
-12.32%
34.64%

SRPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 62.62%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.24
-$5.86
-$0.27
-$0.46
-
Expected
-$1.35
-$1.38
-$1.78
-$1.23
$0.02
Surprise
-7.99%
323.65%
-84.81%
-62.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Sarepta Therapeutics stock

Buy or sell Sarepta Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing